Neuraxis (NRXS) EBITDA Margin (2022 - 2025)
Neuraxis (NRXS) posted EBITDA Margin of 177.34% for Q4 2025, up 31.48% sequentially from 258.82% in Q3 2025, and up 1534.0% YoY from 10.85% in Q4 2024.
Neuraxis (NRXS) EBITDA Margin (2022 - 2025) Analysis & Trends
Neuraxis has reported EBITDA Margin for 4 years, with the latest figure at 177.34% in Q4 2025.
- Quarterly EBITDA Margin rose 1534.0% year-over-year to 177.34% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 219.37% (up 4709.0% YoY) and the FY2025 annual result came in at 219.37%, up 4709.0% from the prior year.
- EBITDA Margin rose to 177.34% in Q4 2025 per NRXS's latest filing, from 258.82% in the prior quarter.
- Over five years, EBITDA Margin peaked at 98.1% in Q2 2022 and troughed at 633.0% in Q3 2023.
- A 4-year average of 243.02% and a median of 194.43% in 2022 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin slumped 43858 bps in 2023, then surged 38530 bps in 2024.
- Over 4 years, EBITDA Margin stood at 160.86% in 2022, then plunged by 90 bps to 305.42% in 2023, then soared by 37 bps to 192.68% in 2024, then grew by 8 bps to 177.34% in 2025.
- According to Business Quant data, EBITDA Margin over the past three periods registered 177.34%, 258.82%, and 192.14% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Neuraxis | 75.51 Mn | 67.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -177.34% |
| Sep 30, 2025 | -258.82% |
| Jun 30, 2025 | -192.14% |
| Mar 31, 2025 | -256.25% |
| Dec 31, 2024 | -192.68% |
| Sep 30, 2024 | -247.71% |
| Jun 30, 2024 | -360.89% |
| Mar 31, 2024 | -283.33% |
| Dec 31, 2023 | -305.42% |
| Sep 30, 2023 | -633.00% |
| Jun 30, 2023 | -172.99% |
| Mar 31, 2023 | -111.32% |
| Dec 31, 2022 | -160.86% |
| Sep 30, 2022 | -194.43% |
| Jun 30, 2022 | -98.10% |